Lumida
/IMNM
⌘K
Immunome Inc

Immunome Inc

IMNM
$22.32USD↑+0.54%+0.12 today

MARKET CAP

2.5B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$22 – $23

52W RANGE

$9
$28

AI Summary

Stalk
Buy NowMedium

IMNM remains in Stage 2 advancing with established higher highs and higher lows, supported by rising EMAs and healthy volume. The recent pullback into the rising EMA zone offers an attractive entry for continuation participation in the momentum trend. Execution is warranted now, targeting shallow pullbacks into the 9/21 EMA support area. A sustained break and close below the 50-day SMA on heavier volume would invalidate this view.

  • ↑FDA acceptance of Varegacestat NDA marks key commercialization milestone
  • ↑344 000 inducement shares awarded, strengthening research team
  • ↓Negative earnings yield highlights weak profitability prospects
Full analysis →
Insider Trades26 trades
Date↓SideTicker↕Insider↕Role↕Shares↕Price↕Mkt Cap↕52W High↕52W Low↕Value↕% Chg↕Rule↕AI View↕
Jul 7, 2026SellIMNMKinney HornCHIEF BUSINESS OFFICER2,184$18.96$2.5B-19.28%+157.59%$41.4K+0.00%10b5-1Buy Now
Jul 2, 2026SellIMNMRobert LechleiderChief Medical Officer110,000$15.68$2.5B-19.28%+157.59%$1.7M+0.00%10b5-1Buy Now
Jun 25, 2026SellIMNMRobert LechleiderChief Medical Officer110,000$14.29$2.5B-19.28%+157.59%$1.6M+0.00%10b5-1Buy Now
Jun 15, 2026SellIMNMMax RosettChief Financial Officer120,000$9.64$2.5B-19.28%+157.59%$1.2M+0.00%10b5-1Buy Now
Apr 2, 2026SellIMNMJack HigginsChief Scientific Officer9,438$21.64$2.5B-19.28%+157.59%$204.2K-30.02%10b5-1Buy Now
Apr 2, 2026BuyIMNMMax RosettChief Financial Officer136,561$11.07$2.5B-19.28%+157.59%$1.5M+1.82%10b5-1Buy Now
Mar 30, 2026SellIMNMJack HigginsChief Scientific Officer6,291$19.30$2.5B-19.28%+157.59%$121.4K-16.67%—Buy Now
Mar 27, 2026BuyIMNMClay B SiegallPresident and CEO25,450$19.67$2.5B-19.28%+157.59%$500.6K+3.83%—Buy Now
Dec 30, 2025BuyIMNMClay B SiegallPresident and CEO4,729$21.15$2.5B-19.28%+157.59%$100.0K+0.72%—Buy Now
Dec 19, 2025SellIMNMJack HigginsChief Scientific Officer6,000$21.44$2.5B-19.28%+157.59%$128.6K+0.00%—Buy Now
Dec 19, 2025SellIMNMClay B SiegallPresident and CEO207,278$0.72$2.5B-19.28%+157.59%$149.1K-11.25%—Buy Now
Dec 19, 2025BuyIMNMPhilip TsaiChief Technical Officer10,000$20.49$2.5B-19.28%+157.59%$204.9K+30.03%—Buy Now
Dec 18, 2025BuyIMNMClay B SiegallPresident and CEO46,511$21.50$2.5B-19.28%+157.59%$1.0M+5.77%—Buy Now
Sep 10, 2025BuyIMNMJack HigginsChief Scientific Officer22,000$1.35$2.5B-19.28%+157.59%$29.7K+12.90%—Buy Now
Mar 27, 2025BuyIMNMJack HigginsChief Scientific Officer5,200$1.35$2.5B-19.28%+157.59%$7.0K+2.78%—Buy Now
Mar 26, 2025BuyIMNMClay B SiegallPresident and CEO137,100$7.29$2.5B-19.28%+157.59%$999.5K+20.47%—Buy Now
Mar 24, 2025BuyIMNMPhilip TsaiChief Technology Officer12,300$8.42$2.5B-19.28%+157.59%$103.6K+58.57%—Buy Now
Jan 31, 2025BuyIMNMClay B SiegallPresident and CEO150,000$7.75$2.5B-19.28%+157.59%$1.2M+28.87%—Buy Now
Nov 21, 2024BuyIMNMRobert LechleiderChief Medical Officer15,805$9.48$2.5B-19.28%+157.59%$149.8K——Buy Now
Nov 21, 2024BuyIMNMPhilip TsaiChief Technology Officer21,000$9.43$2.5B-19.28%+157.59%$198.0K——Buy Now
Nov 21, 2024BuyIMNMClay B SiegallPresident and CEO100,000$9.62$2.5B-19.28%+157.59%$962.2K+11.05%—Buy Now
Sep 19, 2024BuyIMNMMax RosettChief Financial Officer56,380$4.87$2.5B-19.28%+157.59%$274.3K+15.91%—Buy Now
Aug 15, 2024BuyIMNMJack HigginsChief Scientific Officer25,519$2.96$2.5B-19.28%+157.59%$75.4K+6.31%—Buy Now
May 20, 2024BuyIMNMClay B SiegallPresident and CEO100,000$13.88$2.5B-19.28%+157.59%$1.4M+13.91%—Buy Now
Oct 2, 2023BuyIMNMBruce TurnerChief Strategy Officer42,300$5.91$2.5B-19.28%+157.59%$250.0K——Buy Now
Oct 2, 2023BuyIMNMClay B SiegallPresident and CEO169,204$5.91$2.5B-19.28%+157.59%$1.0M+112.48%—Buy Now